Introduction
Metastasis to the bone is one of the most clinically important features of prostate cancer, although relatively little is known about specific pathways that promote tumor growth in the bone. Metastatic prostate cancer is treated with androgen deprivation therapy, which initially reduces symptoms and tumor cell growth, although recurrence of castration-resistant prostate cancer (CRPC) is almost universal (1). Reconstitution of androgen receptor (AR)–mediated signaling is a central mechanism leading to CRPC (2, 3). Although some level of AR output, measured by expression of AR target gene signatures, is almost always observed in prostate cancer, there is significant intertumoral heterogeneity, especially associated with progression (4–6). Following the development of castration resistance, a decrease in the level of an AR gene signature commonly expressed in prostate cancer indicates either reduced AR transcriptional activity or a shift in AR-dependent transcriptional specificity (6, 7). AR output is influenced by factors such as PTEN levels and the differentiation status of tumors (8–10). In the case of PTEN loss or N-cadherin expression, compensatory non-AR pathways are thought to significantly contribute to tumor growth.

Histopathology of end-stage bone metastases acquired at autopsy or as a result of surgical resections for spinal cord compressions or pathologic fractures (11–13) has shown that bone metastases are heterogeneous, even within a single patient. Importantly, although nuclear AR staining is usually prominent in most cells, non-neuroendocrine AR-negative tumor cells are clearly observed in both CRPC and treatment-naive metastases (11–14). These findings imply that AR-independent survival in the bone microenvironment occurs, and the mechanisms contributing to such survival are of great interest. The heterogeneity of metastatic disease suggests that second-generation AR-directed therapies such as abiraterone and enzalutimide most likely will need to be complemented by therapies directed against non-AR pathways.

We describe here the characterization of Fn14 (TNFRSF12A) as a marker of clinical prostate cancer metastases and a determinant of experimental metastatic capability. Fn14, a TNF receptor family member, is the cognate receptor for TWEAK, a TNF-like cytokine, produced most prominently by infiltrating immune cells (15). Fn14 expression is low or absent in most normal tissues but can be activated by physiologic mediators such as mitogens, hormones, and cytokines in epithelial, mesenchymal, and neuronal cell types (16). Activation of the TWEAK–Fn14 axis leads to context-dependent responses, including a prominent role in normal tissue repair and inflammation (15, 16). TWEAK-stimulated Fn14 signaling occurs through multiple pathways, including NFκB, MAPK, and CDC42/RAC (16, 17).
The overexpression of Fn14 has been reported in various solid tumors, where higher Fn14 expression in some tumor types has been shown to correlate with more advanced grade and poorer prognosis (18, 19), although it has not been previously addressed whether Fn14 is functionally required for an aggressive phenotype in vivo. Fn14-targeted agents based upon antibody binding specificities are being developed and have shown promise in preclinical oncology studies as a new class of therapeutics (20, 21). The study described here uniquely addresses the role of Fn14 in the development of bone metastasis, identifies the p50/p65 NFκB pathway as a sufficient and necessary downstream mediator of Fn14-dependent bone metastasis, and establishes an association between Fn14 expression and a low canonical AR gene signature phenotype.

Materials and Methods

shRNA-mediated gene silencing and expression rescue in DU145/RasB1 cells

All genetically engineered cell lines were established using lentiviral vectors following standard procedures (22). Fn14 gene (TNFRSF12A) was silenced with two Fn14 shRNAs in the pLKO.1 lentiviral vector, designed by The RNAi Consortium (TRC; Open Biosystems) and targeting the following sequences: 5′-ATGAATGAATGATGAGTGGGC-3′ (sh1) and, 5′-AGATGGGCCAAAACGACCGG-3′ (sh2). Expression-rescued genes included Fn14 (Genecopeia), IKKβ<sub>S32A,S36A</sub> and NIKAT3 in a pFUGW lentiviral vector with a FerH promoter (23). To achieve controlled expression of target genes, DU145/RasB1 cells stably expressing a Tet-On 3G transactivator were first established and further infected with a pFUGW lentiviral expression clone containing either AR (NM_000044.3) or mutant 1xBt super repressor (1xBtSR; 1xBt<sub>S24A,S96A</sub>) under the control of the TRE3G promoter with an IRES-mCherry reporter. AR or 1xBtSR expression was induced with 1 μg/mL doxycycline.

Chromatin immunoprecipitation assays

Chromatin immunoprecipitation (ChIP) assays were performed using the EZ-Magna ChIP A Kit (Millipore) with a modified protocol (24). ChIP reactions were set up using rabbit monoclonal AR antibody [Clone ER179(2), Epitomics] at 4°C overnight. PCR primers are listed in Supplementary Table S1.

In vivo metastasis assay

Metastatic activity was determined using 6- to 7-week-old male athymic nude mice (Ncr nu/nu) as previously described (22).

Tissue microarray analysis

Tissue microarray analyses (TMA) containing primary prostate cancer (UWTMA48) or metastases (UWTMA22) were constructed at the University of Washington (25). The NYU Prostate Cancer Biochemical Recurrence array, CAP6 TMA, was acquired from the Prostate Cancer Biorepository Network (PCBN; http://www.prostatebiorepository.org).

Immunohistochemical (IHC) staining conditions are described in Supplementary Table S2. The intensity scoring method for Fn14, TWEAK and p65 was 0, none; 1, weak; 2, moderate/intermediate; 3, strong; and 4, strong and obscuring details. The percentages of tumor cells scored for Fn14 and TWEAK were 0, none; 1, up to 25%; 2, up to 50%; 3, up to 75%; and 4, up to 100%. Because a large number of cores contained a low percentage of nuclear p65 staining, an expanded scale was used for scoring: 0, none; 1, up to 10%; 2, up to 25%; 3, up to 50%; 4, up to 75%; and 5, up to 100%. This system yielded a 16 or 20-point combined staining score. For Fn14 and TWEAK, combined scores were <2, negative/weak; 3–6, intermediate; and 8–16, strong. For nuclear p65, combined scores were 0, negative; 1–3, weak; 4–6, intermediate; and 8–20, strong.

Clinical outcome analysis using human tumor datasets

mRNA expression data under the GEO accession numbers GSE21034 (26) and GSE5988 (27) were used. The Taylor dataset represents 151 primary and 19 metastatic tumors from patients treated by radical prostatectomy at Memorial Sloan-Kettering Cancer Center. The Grasso dataset represents a large cohort of heavily pretreated patients with lethal metastatic disease comprising cancer-matched benign prostate tissues, 39 localized prostate cancers, and 35 metastatic CRPCs. The expression data and resulting Z-scores were log<sub>2</sub> normalized.

A previously described androgen-responsive gene signature (28) was used to determine the correlation of Fn14 expression level and AR output. This gene set was scored for each tumor by summing the expression Z-scores within the human prostate cancer cohort. Tumors were median-stratified by Fn14 expression and the mean score of androgen response signature was determined in each group.

Statistical methods

In vivo animal results, TMA analysis, and clinical outcome analysis are expressed as plots showing the median and box boundaries extending between 25th to 75th percentiles, with whiskers down to the minimum and up to the maximum value. All in vitro data were analyzed as mean ± SE. Data were analyzed using Prism software (GraphPad Software, Inc.) and differences between individual groups were determined by the Student t test or ANOVA followed by Bonferroni post test for comparisons among three or more groups. P < 0.05 was considered statistically significant. Log-rank test was used for survival curve analysis. The association of Fn14 and nuclear p65 was analyzed using contingency tables and the Fisher exact test.

Results

Fn14 is required for experimental prostate cancer bone metastasis

We previously described the development of a metastatic prostate cancer xenograft model, based upon the activation of Ras effector pathways in the DU145 cell line (22). Activation of the Ras pathway is commonly observed associated with prostate cancer progression (26, 29). To enrich for bone metastatic activity, DU145 Ras<sup>EGT</sup> tumor cells were isolated from three independent bone metastases and expanded in culture. Inoculation of the bone-derived clones (DU145/RasB), compared with the parental Ras<sup>EGT</sup> transformed cells, demonstrated higher metastatic capacity as determined by more rapid...
development of metastasis and formation of more numerous and larger metastatic lesions (30). To determine whether changes in secreted factors or surface receptors correlated with bone metastatic capacity, supernatants from the cultured parental and bone-derived clones were assayed using a commercial antibody array designed to detect proteins within this functional class. Two of the most robust differences observed in all three bone-derived clones compared with the non-enriched parental culture were increased levels of the cytokine, TWEAK, and its cognate receptor, Fn14 (Fig. 1A). Western blot analyses performed on cell extracts confirmed high cell-associated Fn14 in bone-derived clones (Fig. 1B). To analyze the functional significance in bone metastasis development of the Fn14–TWEAK pathway, Fn14 was depleted in DU145/RasB1 cells using two different lentivirus-encoded Fn14 shRNAs (Fig. 1C). We investigated Fn14 in the development of metastasis because it is anticipated to act cell autonomously. In contrast, TWEAK, a secreted product of the microenvironment, potentially can be contributed by a nontumor source. Depletion of Fn14 had no effect on the in vitro growth rate (Supplementary Fig. S1A). Following inoculation of Fn14-depleted cells, mice developed significantly less bone (Fig. 1D) and brain metastasis (Supplementary Fig. S1C) compared with controls as measured by bioluminescent imaging at week 4 and by the percentage of mice with bone lesions as determined by histology and/or X-ray at morbidity (Table 1). Mice inoculated with Fn14-depleted cells maintained a normal body weight (Supplementary Fig. S1B) and survived longer (Fig. 1E). Morbidity in these

Figure 1. Fn14 pathway activity is necessary for experimental bone metastasis. A, TWEAK and Fn14 protein levels as determined by the protein array analysis of conditioned media from parental DU145 (P), DU145/RasG37 (G37), and three bone metastatic clones (B1, B2, and B3). B, Western blot analysis of whole-cell lysates measuring Fn14 in parental DU145(P), G37, and three bone metastatic clones (DU145/RasB1, B2, and B3). C, Western blot analysis for Fn14 in DU145/RasB1 cells infected with lentivirus vector alone (EV) or lentivirus encoding silencing shRNA directed toward Fn14 (Fn14shRNA1 or Fn14shRNA2). D, bioluminescence signal of bone metastasis per mouse for mice bearing tumor cells described in C at week 4. EV: n = 9; shRNA1 and shRNA2: n = 10 per group; *, P < 0.05 versus control. E, survival curve of tumor-bearing mice in the three groups from D. *, P < 0.05 versus EV. F, the incidence of bone metastasis in mice bearing PC3/EV tumors and mice bearing PC3/Fn14 shRNA1 or two tumors. ***, P < 0.01 versus EV.
mice mainly was due to brain metastasis. The bone metastasis inhibitory effect was rescued by reexpression of Fn14 (Table 1), demonstrating specificity of the phenotype for Fn14 depletion. To address the generality of this finding, we depleted Fn14 in PC3 prostate cancer cells, originally isolated from a patient bone metastasis. PC3 cells express high levels of Fn14, and although depletion did not affect growth in vitro (Supplementary Fig. S1D), it significantly inhibited bone metastasis as measured by bone metastasis development (Figure 1F), tumor burden, and survival (Supplementary Fig. S1E and S1F). Taken together, these data support a functional role for Fn14 in bone metastatic capability.

Fn14 is expressed in a high percentage of clinical prostate cancer metastases

To analyze the prevalence of Fn14 expression in patient samples relative to prostate cancer progression, we performed IHC using antibodies directed against Fn14 in tissue arrays containing a large number of bone and soft-tissue metastases as well as normal prostate, benign prostatic hyperplasia (BPH), and primary prostate cancer specimens (Fig. 2A). Representative images in bone metastases of either weak or strong staining, composed of membranous and cytoplasmic labeling, are shown in Supplementary Fig. S2A. A semi-quantitative scoring system of 0 to 16, reflecting intensity of staining and percentage of positive tumor cells, was used. The mean total score (Fig. 2B) as well as individual intensity and extent (Supplementary Fig. S2B) scores of metastatic samples were significantly higher than samples in the other categories. The distribution of scores is shown in Fig. 2C, illustrating Fn14 expression in 10% of normal prostate epithelium, 25% of BPH, 40% of primary prostate cancer, and 75% of metastatic samples. The distribution of scores between bone and soft-tissue metastases was similar. We next investigated the correlation of Fn14 expression in primary prostate specimens with tumor progression, measured as increasing PSA levels with time after prostatectomy, usually an indication of recurrence outside the prostate (Fig. 2D). Patients with Fn14-positive specimens (22.5% in this array) had significantly shorter time to biochemical recurrence, consistent with published data from an independent cohort of patients (18). These data from patient populations show that Fn14 expression occurs in a significant proportion of clinical bone metastases and support the correlation in primary prostate cancer of Fn14 expression with increased aggressiveness.

An important question concerns the availability of the TWEAK ligand. TWEAK staining in tissue sections was observed across various cellular components, including the cytoplasm, membrane, and extracellular matrix. A high proportion of epithelial cells was stained in most sections, whereas the staining of stromal and immune components was variable (see Supplementary Fig. S2C for examples of staining). Semi-quantitative analyses demonstrated that relatively similar levels of TWEAK ligand are constitutively present in normal and pathologic prostate as well as metastatic tissues (Fig. 2E).

Table 1. The role of the canonical and noncanonical NFκB pathway in bone metastasis development

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>DU145/RasB1 EV</th>
<th>DU145/RasB1 Fn14KD EV</th>
<th>DU145/RasB1 Fn14KD IKKβS177E/S181E</th>
<th>DU145/RasB1 Fn14KD NIKΔT3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone metastasis</td>
<td>14/18 (78%)</td>
<td>5/19 (26.3%)</td>
<td>12/19 (63.2%)</td>
<td>17/18 (94.4%)</td>
</tr>
<tr>
<td>Vs. Fn14KD</td>
<td>***, P &lt; 0.01</td>
<td></td>
<td>*', P &lt; 0.05</td>
<td>NS</td>
</tr>
</tbody>
</table>
| NOTE: Shown are the number and percentage of mice that developed bone metastasis. Fn14-depleted DU145/RasB1 (Fn14KD) were super-infected with lentiviruses expressing the indicated genes. Mice were euthanized at morbidity, between 6 to 9 weeks after tumor cell inoculation. Abbreviation: NS, nonsignificant.

The canonical NFκB pathway reconstitutes Fn14-depleted prostate cancer metastasis

The identification of signaling pathways that contribute to the establishment of prostate cancer bone metastasis is of therapeutic interest. Fn14 signaling activates canonical and noncanonical NFκB pathways, mediated by p65/RELA and p52/RELB complexes, respectively (16). Depletion of Fn14 in DU145/RasB1 cells inhibited TWEAK-stimulated p65 and p52 nuclear translocation by more than 50% (Fig. 3A). To determine whether NFκB pathways are necessary for the development of DU145/RasB1 bone metastases, we made use of a doxycycline-inducible, degradation-resistant IκBαSR, which prevents the translocation of p65 into the nucleus and indirectly inhibits synthesis of the p52 precursor, p100 (31). Prior doxycycline induction of IκBαSR led to inhibition of both NFκB pathways following TWEAK treatment in vitro (Fig. 3B), whereas as Fn14-dependent MAPK pathways were not affected (Supplementary Fig. S3A). Figure 3C shows the experimental design for investigating the influence of NFκB signaling during metastasis development. IκBαSR was induced either from the time of tumor cell inoculation into the arterial circulation (day 0) or after micrometastases had been established (day 14). Expression of IκBαSR beginning at either day 0 or 14 led to significantly less metastases after 4 weeks as compared with control mice (Fig. 3D), although IκBαSR had a relatively less dramatic effect on in vitro cell growth (Supplementary Fig. S3B). The inhibition of metastasis by IκBαSR also was reflected by the maintenance of body weight (Supplementary Fig. S3C) and increased survival (Fig. 3E). These results indicate that blocking NFκB even after the establishment of micrometastases inhibits clinically observable metastasis development.
To determine whether either NFκB pathway individually is sufficient for replacing the Fn14-dependent signal leading to bone metastasis, we used a rescue approach in Fn14-depleted cells. A constitutively active form of IKKβ, IKKβS177E,S181E, was used to reconstitute the p50/p65 pathway, and a truncated form of NIK lacking the TRAF3 binding site (NIKDT3) was used to rescue the p52/RELB pathway (Supplementary Fig. S3D; ref. 23). As shown in Fig. 3F, IKKβS177E,S181E expressing Fn14-depleted cells demonstrated elevated levels of nuclear p65 with or without TWEAK treatment, whereas control cells demonstrated nondetectable nuclear p65. Similarly, NIKDT3-expressing Fn14-depleted cells showed increased p52 nuclear translocation independent of TWEAK treatment (Fig. 3F). Table 1 summarizes the bone metastatic capacity in each group, demonstrating that NFκB activation is sufficient to reconstitute Fn14-dependent metastasis. The bone metastasis phenotype was reconstituted in Fn14-depleted cells by IKKβS177E,S181E expression, whereas NIKDT3 expression alone appeared to be insufficient, suggesting a greater contribution by the p65 pathway. Taken together, these data show that NFκB activation is necessary and sufficient for the development of Fn14-dependent bone metastasis.

Nuclear NFκB p65 is observed in clinical prostate cancer metastases

To determine the prevalence of the canonical NFκB pathway in prostate cancer primary tumors and metastases, tissue arrays previously characterized for Fn14 labeling were stained with an anti-total p65 antibody. Labeling was observed both in the nuclear and cytoplasmic compartments. Nuclear labeling of prostate epithelial cells marked activation of the NFκB pathway. Representative images of total p65 labeling in normal prostate and benign and malignant prostate pathologies are shown in Fig. 4A. A semi-quantitative scoring system of 0-2 was used to score the intensity of nuclear labeling. Table 2 summarizes the prevalence of nuclear p65 labeling in different clinical samples. The number of patient tissue samples is indicated.

Figure 2. Expression of Fn14 in normal and pathologic prostate tissues. A, representative histologic images depicting normal prostate, BPH, prostate cancer (PCa), and bone metastasis stained for Fn14. B, plots summarizing the Fn14 scores in different groups of clinical samples quantified for UWTMA22 and UWTMA48. The number of patient tissue samples is indicated. ***P < 0.001; **P < 0.01; *P < 0.05. C, percentage of tissue samples with negative/weak (0–2, open bar), intermediate (3–6, gray bar), or high (>8, black bar) Fn14 expression from B. The shaded sections of the bars in the metastasis group represent soft-tissue metastasis, whereas the solid sections represent bone metastasis. D, Kaplan–Meier curve of biochemical recurrence rate (BCR) in Fn14-positive (>3) and Fn14-negative (≤2) patient populations from CAP6 TMA. *P < 0.05 with log-rank test. E, average scores for TWEAK staining in epithelium in UWTMA22 and UWTMA48. n = 27 (normal), 28 (BPH), 51 (PCa), and 75 (metastasis).
The NFκB pathway mediates the effects of TWEAK–Fn14. A, Western blot analysis of nuclear p52 and p65 in DU145/RasB1 and DU145/RasB1 Fn14shRNA cells treated with TWEAK for various times. B, Western blot analysis of DU145/RasB1 cells expressing Tet-on TA and TREG3-IkBxSR with and without prior doxycycline induction showing IkBx, p65 (RelA), p52, p100, and Fn14 expression relative to time after TWEAK treatment. IkBx, Fn14, and the p52 precursor, p100, were detected in the cytoplasmic fraction; p65 and p52 were detected in the nuclear fraction. C, schematic of in vivo experimental design. Mice were inoculated on day 0 with DU145/RasB1 cells expressing Tet-on TA and TREG3-IkBxSR. Mice were fed with doxycycline diets starting on day 0 or day 14 to induce IkBxSR expression and imaged weekly to monitor tumor burden. n = 8 to 9 per group. D, BLI analysis of bone and brain metastasis per mouse for tumor-bearing mice described in C. Numbers represent mice that developed metastasis over total mice in each group at week 4. *, P < 0.05 versus control. E, the survival rate of tumor-bearing mice from D. F, DU145/RasB1 cells depleted of Fn14 were superinfected with lentiviruses encoding Fn14, IKKB<sup>177E,S181E</sup>, or NIKT3. The DU145/RasB1 EV cells are shown for comparison. Western blot analysis shows nuclear p65 and p52 translocation with (+) or without TWEAK (−) treatment for 60 minutes. Dox, doxycycline.

Fn14 expression is inversely correlated with AR status

One clinically important property of tumor cells is AR transcriptional output, which can be heterogeneous within...
and between tumors (4, 14). We observed that Fn14 and TWEAK expression were significantly and highly expressed in AR-negative compared with AR-positive prostate cancer cell lines (Fig. 5A), in agreement with published results (18). To determine whether AR signaling was able to influence Fn14 or TWEAK expression in prostate cancer cells, we overexpressed AR in PC3 and DU145 cells using a doxycycline-regulated system. As shown in Fig. 5B, when AR is induced in DU145/RasB1 cells, Fn14 and TWEAK RNA levels were decreased after DHT treatment, whereas the AR antagonist MDV3100 reduced this effect. Consistent with this finding, Fn14 protein levels also were reduced by the presence of AR (Fig. 5C). In LAPC4 cells, Fn14 protein levels were regulated by endogenous AR in the anticipated pattern, demonstrating decreased and increased levels with DHT and MDV3100 treatment, respectively (Fig. 5D).

To interrogate Fn14 and TWEAK expression in patient populations, we analyzed a microarray dataset from Memorial Sloan-Kettering Cancer Center composed of 131 primary and 19 metastatic prostate cancer samples (26). Because TWEAK and Fn14 expression appeared to be regulated approximately in parallel in cell lines, we analyzed the relative expression of the two genes in individual patient samples. Interestingly, Fn14 and TWEAK RNA levels in individual patients revealed a significant correlation (R = 0.59; P < 0.0001; Fig. 6A). TWEAK protein levels tend to be constitutively present, whereas Fn14...
protein levels increase with progression (Fig. 2), implying that there may be different posttranscriptional regulation of TWEAK and Fn14. We then analyzed AR pathway activation relative to Fn14 mean-stratified expression by using a previously reported mRNA signature of AR target genes (28), which demonstrated an inverse relationship between Fn14 expression and AR transcriptional output (Fig. 6B). This finding was validated in an independent dataset (27) for a cohort of CRPC samples (Supplementary Fig. S4A). The Fn14-high samples demonstrated more variability in the AR activity signature than the Fn14-low samples, suggesting more heterogeneity within Fn14-high prostate cancers.

**AR downregulates the transcription of TWEAK and Fn14**

To analyze whether AR directly regulates the transcription of Fn14 and TWEAK, potential androgen receptor response elements (ARE) were mapped in the TWEAK and Fn14 promoter/enhancer regions (Fig. 6C). LNCaP cells, which express endogenous AR, were used to perform ChIP assays with anti-AR antibodies, which confirmed AR binding to two AREs (A1 and A3) in TWEAK and two AREs (A5 and A7) in Fn14 upstream regions (Fig. 6D). Similar ChIP results were obtained in doxycycline-induced AR-expressing DU145 cells (DU145-AR; Supplementary Fig. S4B). In LNCaP, binding sites for FOXA1, an AR complex cofactor, were detected at the same positions as AR
To determine whether AR activation was able to directly regulate TWEAK and Fn14 transcription, the TWEAK upstream region between −4,006 and −2,183 and the Fn14 upstream region between −2,434 and +1 were separately cloned into an RFP reporter construct and transfected into LNCaP cells. The two reporters demonstrated approximately similar activity patterns. AR transcriptional activation with DHT suppressed reporter activity, whereas suppression of basal AR transcription with the AR antagonist, MDV3100, induced reporter activity (Fig. 6E). Mutations in the defined ARES, especially TWEAK A1 and Fn14 A7, decreased DHT-dependent suppression and MDV-dependent induction relative to no treatment, demonstrating AR-mediated effects. Consistent with the results in LNCaP cells, AR-mediated suppression of reporter activity also was observed upon doxycycline induction in DU145 cells (Supplementary Fig. S4C). Taken together, these data suggest that AR binding to Fn14 and TWEAK upstream regions is transcriptionally suppressive.
Because higher Fn14 and TWEAK RNA levels in patient samples correlate with lower AR signature gene expression, Fn14 and TWEAK may represent genes expressed in association with overall lower AR activity or altered AR specificity.

Discussion

Although bone metastasis is a primary reason for morbidity and mortality in patients with progressive prostate cancer, relatively little is known about the mechanisms responsible for establishing and expanding prostate cancer bone metastases (34). Using experimental models in addition to molecular and histologic analyses of clinical samples, we present evidence that Fn14 is one determinant of prostate cancer bone metastatic capacity. Fn14 staining also has been observed in about 50% of clinical breast cancer bone metastases, although the number of samples analyzed was small (35).

Of particular interest, Fn14 expression suggests a mechanistic link between prostate cancer bone metastasis and inflammation as the TWEAK–Fn14 axis promotes local inflammation (15). An inflammatory microenvironment in the bone contributes to the so-called ‘vicious cycle’ mediated by interacting stromal, immune, and tumor elements and resulting in bone remodeling and enhanced tumor cell survival and proliferation (36). From the data presented here, it seems that Fn14-expressing prostate cancer cells often produce autocrine TWEAK in addition to TWEAK secretion from infiltrating inflammatory cells. The bone metastasis model used in this study identifies the Fn14 pathway as one upstream regulator of NFB signaling in prostate cancer, and shows that the canonical NFB pathway is sufficient to replace Fn14 downstream signaling in this context. Fn14-mediated responses are usually proinflammatory as a result of NFκB induction of inflammatory proteins, including cytokines, chemokines, adhesion molecules, and metalloproteases (37). Thus, Fn14-dependent tumor responses are anticipated to increase inflammatory cell infiltration and activation. In addition, the Fn14–TWEAK axis has been shown to autonomously regulate tumor cells with respect to survival, proliferation, migration, and progenitor expansion (15, 16). Thus, both autonomous and nonautonomous Fn14-mediated functions may contribute to prostate cancer bone metastasis.

Our data are consistent with various preclinical models that support a role for NFB in prostate cancer metastasis. An alternative mechanism of NFB activity, loss of the DAB2IP tumor suppressor, leading to experimental prostate cancer soft-tissue metastasis has been described (38). Of interest, coordinated RAS and NFB activation occur in the DAB2IP model and in the model investigated here. DAB2IP loss regulates both RAS and NFB activation, whereas the DU145/Ras model expresses constitutive RAS activation in addition to Fn14-regulated NFB. It remains an open question as to how directly or indirectly RAS signaling is associated with Fn14 and TWEAK expression in prostate cancer. In another study, the manipulation of NFB pathway components in human prostate cancer cell lines demonstrated that NFB activation is necessary and sufficient for tumor cell growth following intratibial injections (39). Finally, a role for the NFB pathway has been implicated in models of castration-resistant growth (40, 41); castration resistance strongly correlates clinically with the development of metastasis (12, 13).

The increased presence of NFκB signaling in tumor tissue relative to normal tissue and a positive correlation with Fn14 expression was confirmed with IHC staining for nuclear p65 (Fig. 4). The low frequency of positive cells may reflect the normally transient nature of p50/p65 signaling, and are consistent with a recent study showing a significant association of even low numbers of nuclear p65 positive cells with higher Gleason score, increased biochemical recurrence, and the development of metastases (32, 42, 43). Fn14 expression is regulated by a variety of extracellular stimuli, including growth factors and hormones, although the molecular mechanisms of such regulation are mostly unknown (16). As shown here, Fn14 expression seems to increase in prostate cancer cells in which AR activity is suppressed, intrinsically low, or shifted in specificity. We describe an AR-dependent, negative regulatory component influencing TWEAK and Fn14 expression in prostate cancer cells. (Fig. 6). The ability to identify prostate cancer cells with a modified AR response, which are anticipated to be less sensitive to androgen deprivation therapy (ADT), is of potential utility considering the inter- and intratumoral heterogeneity of prostate cancer (4–6). Thus, an Fn14-targeted agent may permit the imaging and/or therapeutic treatment of metastatic tumors, especially cells that escape first-line ADT due to modified AR signaling.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: J. Yin, Y.-N. Liu, K. Kelly
Development of methodology: J. Yin, Y.-N. Liu, H. Tillman, B. Barrett
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J. Yin, H. Tillman, B. Barrett, S. Hewitt, L. Fang, R. Lake, E. Corey, C. Morrissey, R. Vessella
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J. Yin, Y.-N. Liu, H. Tillman, B. Barrett, S. Hewitt, L. Fang, E. Corey
Writing, review, and/or revision of the manuscript: J. Yin, Y.-N. Liu, H. Tillman, S. Hewitt, E. Corey, C. Morrissey, K. Kelly
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J. Yin, Y.-N. Liu, H. Tillman, B. Barrett, K. Ylaya, L. Fang
Study supervision: J. Yin, K. Kelly

Acknowledgments

The authors thank Drs. Celestia Higano, Martine Roudier, Lawrence True, Paul Lange, Bruce Montgomery and Peter Nelson.

Grant Support

This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. Y.-N. Liu was supported by the New Staff Research Project Grant, Taipei Medical University, Taiwan (TMU/101-3E1-B20). The Prostate Cancer Donor Program is supported by the Pacific Northwest Prostate Cancer SPORE (P50CA97186), the PO1 NIH grant (PO1CA085859), and the Richard M. Lucas Foundation.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 12, 2013; revised May 20, 2014; accepted May 31, 2014; published OnlineFirst June 26, 2014.
References


AR-Regulated TWEAK-FN14 Pathway Promotes Prostate Cancer Bone Metastasis

JuanJuan Yin, Yen-Nien Liu, Heather Tillman, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-3233

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2014/06/27/0008-5472.CAN-13-3233.DC1

Cited articles
This article cites 43 articles, 16 of which you can access for free at:
http://cancerres.aacrjournals.org/content/74/16/4306.full.html#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
/content/74/16/4306.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.